Cumberland Pharmaceuticals Closes Strategic Transaction with Apotex

Executive Summary

• Cumberland Pharmaceuticals has closed a strategic transaction with Apotex Health Corp., resulting in the acquisition of Cumberland's line of branded pharmaceuticals for $100 million in cash.
• The transaction was approved by Cumberland shareholders with over 99% of votes cast in favor.
• Cumberland will retain its innovative product candidates and majority ownership in Cumberland Emerging Technologies Inc., shifting its strategic focus to its rare disease pipeline, specifically the development of ifetroban.

Key Details

• Transaction Value: $100 million in cash consideration, funded at closing.
• Counterparties: Cumberland Pharmaceuticals Inc. (Seller) and Apotex Health Corp. (Buyer).
• Asset Acquired: Cumberland’s line of branded pharmaceuticals.
• Shareholder Approval: Over 99% of votes cast approved the transaction.
• Strategic Shift: Cumberland retains its pipeline and majority ownership in Cumberland Emerging Technologies Inc., focusing resources on ifetroban development.
• Pipeline Update - Duchenne Muscular Dystrophy Cardiomyopathy:
  • Ifetroban showed breakthrough results in a Phase II clinical study.
  • FDA interactions are ongoing regarding study results and approval requirements.
  • The program holds FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations.
• Pipeline Update - Systemic Sclerosis:
  • Phase II study evaluating safety is complete; data evaluation is underway.
  • Top-line results are anticipated as the next milestone.
• Pipeline Update - Idiopathic Pulmonary Fibrosis:
  • Phase II study is actively enrolling at medical centers across the U.S.
  • Favorable interim safety findings have been announced.
  • Efficacy results are the next milestone.
• Pipeline Update - Cancer Metastasis:
  • Pilot Study results (in collaboration with Vanderbilt Health) suggest ifetroban may block cancer metastasis.
  • A favorable trend was identified with fewer deaths due to metastatic disease in the ifetroban group compared to placebo.
  • Phase 2 clinical trial found ifetroban safe and well-tolerated in oncology patients, supporting further development.

Notable Quotes

• "We are pleased to complete this value-creating transaction, which was strongly supported by our shareholders with over 99% of the votes cast in favor of the transaction... This milestone significantly strengthens our financial position, enabling us to focus on the large market opportunities associated with our pipeline programs." — A.J. Kazimi, CEO of Cumberland